Renin-angiotensin (RAS) genes, a group of promising candidate genes involved in essential hypertension (EH), play a key role in blood pressure regulation. Recently, a series of novel RAS gene polymorphisms were reported, which significantly influence the rate of the gene transcription. This study was designed to explore the association between the RAS gene polymorphisms and EH in a remote countryside population. We examined six polymorphisms in the main component genes of RAS: angiotensin-converting enzyme (ACE) (I/D), angiotensinogen (AGT) (A-6G, A-20C, G-217A and T174 M) and angiotensin type 1 receptor (AT1R) (A1166C). Six polymorphisms were genotyped by gene chip technology. Association studies were performed in 220 EH patients and 235 normotensives.
Introduction
Essential hypertension (EH) is a common complex disease caused by both genetic and environmental factors. 1 High blood pressure (BP) often leads to a series of pathologies, such as insulin resistance, abnormal metabolism of blood glucose and lipids as well as increased risks of various cerebrovascular and cardiovascular diseases, all of which are detrimental to human health condition. Although the precise aetiology of EH remains unclear, accumulating evidence has suggested that genetic susceptibility is an important factor for the development of EH. In 1992, Jeunemaitre et al. 2 
first
reported that AGT gene polymorphism might contribute to the prevalence of EH in Caucasians, which energized an intensive research effort focusing on the EH-associated genes. Up-to-date, many EH candidate genes have been characterized, which are associated with the reninangiotensin system (RAS), the sympathetic nervous system, sodium and electrolyte balance and intracellular messengers. The proteins encoded by these genes have been demonstrated to participate in BP regulation by various biochemical and physiological pathways in the development and progression of EH. Among all these genes which play a role in the aetiology of EH, those encoding for the main components of the RAS are deemed the most probable candidate genes of EH as the RAS system plays an essential role in BP regulation by maintaining vascular tone and water-to-sodium balance. 3 As a result, RAS genes encoding for angiotensinogen (AGT), angiotensin type 1 receptor (AT1R) and angiotensin-converting enzyme (ACE) have been widely investigated in different ethnic populations. [4] [5] [6] [7] [8] In addition, recent studies have shown that the promoter variants of AGT gene significantly influence the rate of AGT transcription and plasma AGT. 9, 10 Conflicting or even contradictory reports have been seen regarding the association between RAS gene polymorphisms and EH incidence, of EH. It is possible that patient selection, environmental factors, genetic allele combinations and antihypertensive therapy may contribute to the inconsistent data from clinical studies on genetic polymorphisms of EH.
11 Given these limitations, this study was designed and performed in the countryside of Dongtai area of Southern China. All subjects had homogeneity of environments, which should minimize the potential influence of mixed factors on EH occurrence to the greatest extent.
On the basis of previous arguments and potential functional polymorphisms, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] we hypothesized that genetic polymorphisms in RAS genes, including AGT A-6G, A-20C, G-217A and T174 M, AT1R A1166C and ACE I/D, was associated with the occurrence of EH. The genotype, allele and haplotype frequencies were compared between the hypertensive and normotensive individuals, in an effort to explore the association between the six SNPs of RAS genes and EH in the population of Southern China.
Methods

Subjects
The study sample was selected from the countryside of Dongtai country, Yancheng city, Jiangsu province, China. The subjects of the study comprised of 455 men and women (40-80 years of age), randomly selected from the countryside registry and stratified by gender and age in 5-year intervals. A case-control study was performed between 220 subjects in the hypertensive group and 235 subjects in the normotensive group.
Inclusion criteria:
(1) Hypertension was diagnosed according to the diagnostic standard of hypertension set by WHO/ ISH in 1999 (systolic blood pressure X140 mm Hg and/or diastolic blood pressure X90 mm Hg). (2) Normotensives were selected from the same population with SBP o140 mm Hg and DBP o90 mm Hg and the absence of hypertension disease history. (3) The enrolled participants completed standard questionnaires by a face-to-face interview. The subjects were Han Chinese ethnicity with a longterm local residence rather than immigrants from other areas. All subjects had not administered any antihypertensive drug treatment to lower blood pressure prior to study enrolment.
Exclusion criteria:
(1) The subjects with secondary hypertension in the hypertensive group and subjects with a family history of hypertension in the normotensive group were excluded from the study. (2) Those with chronic liver and kidney diseases, and diabetes mellitus in both hypertensive and normotensive groups were excluded from the study following a full biochemical and assistant examination.
The study was conducted in accordance with the principle outlined in the Helsinki declaration for the investigation of human subjects. The study protocol was approved by our Institutional Review Board of Nanjing Medical University. Informed consent was obtained from each participant of the study.
Genotype
The genotyping procedure was described earlier. 12 Briefly, genomic DNA was extracted from human peripheral blood with FlexiGene DNA Kit (250) (Qiagen, cat. no. 51206, Frankfurt, Germany). The Primer3 software (http://www.genome.wi.mit.edu/ cgi-bin/primer/primer3.cgi) was applied to design primers prior to multiplex polymerase chain reaction (PCR). Two allele perfect match probes and one mismatch probe were designed respectively for each SNP. The chips were prepared with the OmniGridTM 100 TLC sample (GeneMachine, San Carlos, CA, USA). Genotype was judged by calculating the allele score of the SNP. DNA direct sequencing was conducted to verify the results.
Statistical analysis
These data were statistically analysed with the SPSS 11.5 software (SPSS Inc., USA).
One-way analysis of variance (ANOVA) was used to compare mean values between groups. Frequencies were compared by a w 2 analysis. The relationship between genotypes and the risk of hypertension was expressed in terms of the odds ratios (OR) adjusted for possible confounding effects including gender, age and BMI.
For multivariate risk predictors, the forward stepwise multiple logistic regression analysis was performed. All independent factors, including genotypes and clinical risk factors of EH with nominal Po0.2 were presented in the initial regression mode as doubtful risk factors and forward stepwise regression analysis was used to assess the risk factors using a nominal Po0.05.
A value of Po0.05 was considered statistically significant. Data were presented as mean ± s.d.
Results
Clinical characteristics of the participants Six SNPs (AGT A-6G, A-20C, G-217A and T174 M, AT1R A1166C and ACE I/D) in RAS genes were genotyped successfully in 220 EH and 235 normotensive patients. Clinical characteristics of all 455 subjects are presented in Table 1 . The hypertensive group exhibited a significantly higher systolic blood pressure, diastolic blood pressure, BMI and BUN than the normotensive group. There were no significant differences in other indices between the two groups.
Association analysis between polymorphisms and essential hypertension Three SNPs (AGT A-6G, AGT T174 M and ACE I/D) displayed significant differences in the allele and genotype frequencies between hypertensive and normotensive groups (Tables 2 and 3 ). The allele frequencies of AGT A-6G with G allele, T174 M with T allele and ACE I/D with D allele were much higher in the hypertensive group (Po0.05).
The haplotypes composed of the four SNPs in the AGT gene are shown in Figure 1 . Five inferred haplotypes with frequencies of more than 6% were examined to determine their association with hypertension in all subjects. The frequency of haplotype H1(-6A, 174C, -217G and -20A) in the hypertensive group was significantly lower than that in the normotensive group (w 2 ¼ 10.92, P ¼ 0.001). Furthermore, the logistic regression analysis suggested that the H1 overtly reduced the risk of EH (OR ¼ 0.64; 95% CI ¼ 0.49-0.83), following adjusting the confounding factors of gender, age and BMI.
On further analysis, it was revealed that AGT A-6G, T174 M and ACE I/D were significantly associated with EH (AGT A-6G: AG þ GG vs AA; OR ¼ 1.36; 95% CI ¼ 1.04-1.77. T174M: CT þ TT vs CC; OR ¼ 1.45; 95% CI ¼ 1.15-1.90. ACE I/D: ID þ DD vs II; OR ¼ 1.171; 95% CI ¼ 1.00-1.37) ( Table 2 ). There was no significant difference in the pattern of genotype distribution of AT1R A1166C, AGT A-20C and G-217A.
In addition, the forward stepwise multiple logistic regression analysis revealed that ACE-I/D DD and BMI might effect EH independently. The results indicated that BMI and ACE-I/D DD genotype might be positively correlated with the prevalence of EH.
Discussion
In this study, we investigated the association between six polymorphisms in RAS genes and the risk of EH in a subpopulation from Southern China.
With regard to biases that may lead to potential false-positive or false-negative results, our study was carefully designed and performed in a somewhat unique population. All participants reside in the regions with a lower level of economical development and less migration. The population had homogeneity of environments and never took any antihypertensive intervention (for normotensive subjects). Therefore, these subjects were more suitable to our study purpose than the common source from hospital outpatients for evaluating the genetic background of EH. Our results showed that the genetic frequencies at AGT A-6G, T174 M and ACE I/D sites were significantly different between the hypertensive and normotensive groups. However, there was no significant difference at AT1R A1166C, AGT G-217A and A-20C loci between the two groups. The AGT gene encodes for the precursor molecule for angiotensin II (Ang II), which causes profound vasoconstriction with an increased BP. As an association has been identified between the common variant of M235 T in the AGT gene and EH occurrence, 2 several studies were performed in an effort to identify other genetic polymorphisms which may influence BP. [13] [14] [15] [16] A community-based study showed that the T174 M and M235 T polymorphisms were associated with the onset of EH in Japanese, especially in those consuming high-salt diet, 15 and this was consistent with the findings from our current study.
Recently, an intense attention has been made towards the physiological relevance of the promoter of the AGT gene. 9, 10, 13, 14 Several functional studies have indicated that AGT A-6G, A-20C and G-217A polymorphisms in the promoter region play important roles in regulating the AGT gene transcription and expression. [17] [18] [19] In a recent study, Dickson et al. 10 further testified the hypothesis that the polymorphisms in the AGT promoter may affect cell function, specifically regulation in the level of AGT transcription in AGT-producing tissues. We can assume that AGT gene transcription may be induced by the activity of several AGT gene variants, leading to the increased level of plasma AGT. As a result, the RAS system is further activated to exert a potent regulatory effect on BP. If the promoter variants in the AGT gene are functional as reported, 9,10 we would expect an immediate association between one or more polymorphisms in the AGT gene and EH occurrence. Evidence has been provided that the polymorphism at A-6G site is associated with the level of plasma AGT and the value of BP. 20 However, in another study, an association between A-6G and EH was not identified in Caucasians or African Americans. 5 To evaluate the potential influence of the AGT gene on EH, we performed a haplotype analysis between the four SNPs of the AGT gene and the risk of EH. It might be more significant to detect the genetic factors because of the larger number of alleles as compared with the number of genotypes. Our analyses identified a haplotype, which was significantly more common among normotensives, indicating a protective role against hypertension. (OR ¼ 0.64; 95% CI ¼ 0.49-0.83). The haplotype of AGT is composed of -6A, 174C, -217G and -20A alleles, all of which are considered wild types, indicating a recessive influence on EH. We may postulate that the haplotype composed by four variant alleles increases the risk of EH, although convincing supporting data are still lacking. In our study, it is interesting to note that -6A and 174C are more frequently distributed among normotensives using both allelic and haplotype analysis. This reasserts the protective role of these alleles. The number of cases for haplotype analysis is somewhat insufficient to draw any reliable conclusion. This hypothesis requires consolidation by larger sample studies. Nevertheless, the results support the postulation that multiple variants in the AGT gene influence BP regulation. Last but not the least, the ACE I/D is a common variant in the ACE gene. There has been some evidence suggesting that the ACE D allele significantly influences ACE plasma levels, 21 especially in males. 22 Consistently, our data showed that the ACE I/D polymorphism was associated with EH in this population.
We also combine the genetic and environmental factors (for example, sex, age, BMI, total cholesterol, triglyceride and high density lipoprotein). Our data suggested that BMI and ACE-I/D DD genotype might independently determine the risk of EH. However, no polymorphism in the AGT gene entered the regression mode, which may be caused by potential gene-gene interaction or small sample size.
EH is a disease involving multiple genes and genetic polymorphisms. It is believed that any single gene or its polymorphism is capable of affecting, albeit weakly, the onset and progression of EH. 23 It is probably one of the main reasons contributing to the inconsistent results from various studies.
In conclusion, this study has provided further evidence that ACE-I/D DD genotype and BMI may act independently on the prevalence of EH, and the AGT T174 M and A-6G are closely associated with EH. Although, the haplotype of AGT composed of -6A, 174C, -217G and -20A alleles may be negatively associated with the risk of EH. The main limitation of this study includes relatively low sample size, which did not allow a gender-based analysis. Nonetheless, our study still indicated that genetic polymorphisms in RAS genes might be associated with EH. A larger scale study with independent samples is warranted to further validate our findings.
